NLRP3 and Alzheimer disease: Recent evidence suggests that targeting the NLRP3 inflammasome may also represent a promising therapeutic approach in AD, including results showing the deletion of its Nod-like receptor can abrogate both amyloidosis and tauopathy [33, 151].